Expert Interview
Another View: A discussion of Nexletol (Bempedoic acid) and CLEAR Cardiovascular Outcome Trial ahead of detailed data at ACC
Ticker(s): ESPRInstitution: Trinity Health
- Non invasive cardiologist at Trinity Health (Michigan); fellowship trained at Henry Ford Hospital.
- Manages 250 patients with severe hypertriglyceridemia; 20-30% of patients that don't achieve desired LDL goals with statins alone.
- Specializes in heart failure, valvular disease, coronary disease, echocardiography, pericardial disease, arrhythmias and lipid management.
- Have you had any issues getting Nexletol covered for your patients versus the PCSK9? And how much is out-of-pocket for your patients?
- Do you know anything about patient refill rate or AE profiles?
- When the full results are released on March 4th, do you have a relative risk reduction level that you want to see or that you feel like you need to see to be competitive?
- We've spoken with another doctor who said that the guidelines have really evolved to treat LDL even more aggressively. Could this agent be used in combo therapy or triple therapy down the road?
- I wanted to ask you about hs-CRP as a kind of biomarker. Some studies have shown that it might affect MACE reduction, and the CLEAR outcome study has high levels of hs-CRP.
- Knowing that we have a positive outcome in the trial and the key secondaries, what are your commercial expectations for the drug going forward?
- I wanted to ask you some questions about where this goes in the armamentarium going forward, because there are always newer agents and options. Do you need outcomes data for anything that comes after LDL lowering?
I've seen gene editing in small patient sizes have some amazing effects in LDL lowering, but do you see a path forward for that technology?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
